

CURRICULUM VITAE**JASON J. PARIS, Ph.D.**

Contract Research Division
 Arkana Laboratories
 10810 Executive Center Dr., Ste. 100
 Little Rock, AR 72211
 Ph.: 501.604.2695
 Fax: 501.604.2699
 Email: jason.paris@arkanalabs.com

EDUCATION

Ph.D., Behavioral Neuroscience, The University at Albany-SUNY, Albany, NY	2011
B.S., Psychology, Marywood University, Scranton, PA	2004

PROFESSIONAL POSITIONS

Director, Contract Research, Arkana Laboratories Department of Clinical Trials, Little Rock, AR	2022-present
Research Associate Professor, University of Mississippi Department of BioMolecular Sciences, University, MS Research Institute of Pharmaceutical Sciences, University, MS	2022-present
Director, Neuropharmacology Core, University of Mississippi, School of Pharmacy, University, MS	2021-2022
Director, Bioenergetics Phenotyping Core, University of Mississippi, School of Pharmacy, University, MS	2019-2022
Assistant Professor of Pharmacology, University of Mississippi Department of BioMolecular Sciences, University, MS	2017-2022
Research Assistant Professor, University of Mississippi Research Institute of Pharmaceutical Sciences, University, MS	2017-2022
Postdoctoral Fellow, Virginia Commonwealth University Department of Pharmacology and Toxicology, Richmond, VA	2014-2017
Postdoctoral Fellow, Torrey Pines Institute for Molecular Studies Department of Pharmacology and Neuroscience, Port Saint Lucie, FL	2011-2014
Graduate Research Associate, The University at Albany-SUNY Center for Minority Health Disparities, Albany, NY	2010-2011
Graduate Research Assistant, The University at Albany-SUNY Department of Psychology, Albany, NY	2005-2010
Mental Health Technician, Allied Services Mental Health Division, Scranton, PA	2003-2005
Research Technician, Marywood University Department of Biology, Scranton, PA	2002-2004

CURRENT EXTRAMURAL FUNDING

- R44 DK138688, NIDDK, Total Costs: \$1,926,566
 PI: Larsen CP Co-I: Paris, JJ 9/15/23 – 8/31/25
A proprietary digital platform for precision patient identification and enrollment of clinical trials for rare kidney diseases
- R41 EB036916, NIBIB, Total Costs: \$306,556
 PI: Werfel TA, Walker GM, Heath K Co-I: Paris, JJ 9/15/24 – 8/31/25
Microdosing Implant to Mitigate Depression Associated with Opioid Use Disorder
- R01 DA052851, NIDA, Total Costs: \$1,450,864
 PI: Paris JJ, Ashpole NM Co-I: ElSohly, MA 8/1/20 - 7/31/25 (NCE)
Anti-inflammatory Effects of Novel Minor Cannabinoids and Terpenes on Cellular and Murine Models of HIV and HIV Proteins
- R01 DA056875, NIDA, Total Costs: \$2,846,400
 PI: Tanner EL, Paris JJ Co-I: Traina-Dorge V, Braun S 7/15/23 - 5/31/28
Ionic liquid-assisted drug delivery to brain reservoirs for treatment of neuroHIV
- R01 DA056875-02S1, NIDA, Total Costs: \$72,296
 PI: Tanner EL, Paris JJ Co-I: Traina-Dorge V, Braun S 7/15/23 - 5/31/28
Administrative Supplement for Continuity of Biomedical and Behavioral Research Among First-Time Recipients of NIH Research Project Grant Awards
- R01 DA057317, NIDA, Total Costs: \$2,155,695
 PI: Willett KL, Ashpole NM Co-I: Paris JJ, Bloomekatz J 7/1/24 - 5/31/29
Vulnerability and Persistence of Neuroinflammation and Behavioral Deficits from Developmental Cannabinoid Exposure
- Supplement to P20 GM103476, NIGMS, Total Costs: \$378,100
 PI: Werfel T Co-I: Ashpole NM, Paris JJ 9/01/23 - 8/31/28
MS INBRE: Bioenergetic Cell Phenotyping Core

COMPLETED EXTRAMURAL FUNDING

- R01 EB034086, NIBIB, Total Costs: \$2,417,396 9/26/22 - 06/30/27
 PI: Watkins DL Co-I: Tanner EL SrPers: Delcamp J, Hammer N, Paris JJ, Werfel T
Ionic Liquid-Coated NIR-II Polymer Conjugates as Targeted Brain Theranostics
<Cancelled in 2025 due to changes in HHS/NIH priorities>
- Supplement to P30 GM122733, NIGMS, Total Costs: \$73,000
 PI: Paris, JJ, Willett KL 6/01/23 - 5/31/24
Effects of cannabinoid exposure on mitochondrial bioenergetics and developmental adverse outcomes
- R00 DA039791, NIDA, Total Costs: \$746,300
 PI: Paris JJ 9/1/17 - 8/31/21 (NCE)
Opiate abuse and sex steroids influence neuroAIDS pathology
- S10 OD026751, NIH OD, Total Costs: \$213,606
 PI: Paris, JJ 6/15/19 - 6/14/20
Agilent Seahorse XFe96 Analyzer
- P30 GM122733 (Adm. Suppl. Pilot Project), NIGMS, Total Costs: \$100,000
 PI: Paris, JJ; Co-I: Kaufman, M 2/1/19 - 5/31/20
Natural Neuroendocrine Modulators for HIV-Accelerated Aging
- K99 DA039791, NIDA, Total Costs: \$225,550
 PI: Paris, JJ 8/1/15 - 7/31/17
Opiate abuse and sex steroids influence neuroAIDS pathology

COMPETITIVE AWARDS and HONORS

2020	New Investigator Research Award, Univ. Mississippi School of Pharmacy	\$1500
2018	Travel Award from Winter Conference on Brain Research	\$1000
2016	Postdoctoral Scholar Award, Pharmacology & Toxicology Dept., VCU	
2016	Cold Spring Harbor Lab Trainee: Cellular Biology of Addiction (Cambridge, UK)	
2015	Travel Award from Society for Neuroscience	\$500
2014	Arthur Falek Early Career Investigator Poster Award (2 nd place, SNIP)	
2013	Travel Award from the College on Problems of Drug Dependence	\$1360
2012	Travel Award from International Narcotics Research Conference	\$900
2012	Travel Award from National Institute on Drug Abuse	\$750
2009	University at Albany-SUNY, Psychology Department	\$200
2009	NIH, Neuroscience Microarray Consortium (R01 Supplement)	\$3150
2009	NIH, Neuroscience Microarray Consortium (R01 Supplement)	\$3150
2009	Travel Award from Society for Neuroscience	\$750
2009	Travel Award from NSF, Steroids and Nervous System	\$2000
2008	NIH, Neuroscience Microarray Consortium (R01 Supplement)	\$3150
2008	NIH, Neuroscience Microarray Consortium (R01 Supplement)	\$3150
2007	NIH, Neuroscience Microarray Consortium (R01 Supplement)	\$3150
2007	1 st annual Suzannah Bliss Tieman Research Award, N.E.U.R.O.N.	
2006	Travel Award from International Neuroendocrine Foundation	\$350
2004	Travel Award from National Institute on Alcohol Abuse and Alcoholism	\$2000
2004	Travel Award from Marywood Undergraduate Research Forum	\$395
2003	Grant in Aid of Research, Sigma Xi, Scientific Research Society	\$170

GRANT-RELATED SERVICE

4/3/25	NIH SRG, 2025/05 ZRG1 DCAI-B (04) M
2/24/25	NIH SRG, 2025/05 ZDA1 MXY-N (M1) R
10/21/24	NIH SRG, 2025/01 ZDA1 MXY-N (J2) R
3/26-3/27/24	NIH SRG, HIV Comorbidities and Clinical Studies Study (HCCS)
7/28/23	NIH SRG, ZDA1 JRB-N O1 R
12/6/22	NIH SRG, Pathogenic Mechanisms influencing Blood Brain Barrier function in HIV and Substance Use Disorders
3/30-3/31/22	NIH SRG, 2022/05 ZRG1 EMNR-A (53) R
11/8-11/9/21	NIH SRG, HIV molecular virology, cell biology, and drug development (HVCD)
7/26/21	NIH SRG, ZRG1 IDIB N02
5/5/21	DC CFAR, Pilot Awards Program
11/23-11/24/20	NIH SRG, HIV molecular virology, cell biology, and drug development (HVCD)
6/1-6/5/20	NIH SRG, 2020/10 ZDA1 SXM-M (01) S
4/6/20	NIH CRG, 2020/05 ZRG1 AARR-E (02) M
3/10-3/11/20	NIH SRG, HIV molecular virology, cell biology, and drug development Study Section (HVCD)

ADDITIONAL SERVICE

2021-present	Review Board Member, <i>Cells</i>
2020-2022	Member, Univ. Mississippi Institutional Animal Care and Use Committee
2020-2021	Editorial Board Member, <i>Cells</i>
2020-present	Review Board Member, <i>Nutrients</i>
2019-present	Faculty Liaison, Univ. Mississippi Postdoctoral Association (UMPDA)
2017-present	Mentor, Univ. Mississippi Neuroscience Minor Program
2017-present	Mentor, STEMS Research Experience for Undergraduates Summer Program
2017-2020	Secretary, Univ. Mississippi School of Pharmacy Faculty Council

PROFFESIONAL MEMBERSHIPS AND COMMUNITY OUTREACH

2022-present	American Society of Nephrology	Member
2020-2022	Rho Chi Pharmacy Honors Society	Member
2017-present	Winter Conference on Brain Research	Member
2017-present	American Society for Neurochemistry	Member
2016-2017	Postdoctoral Association, VCU	President
2015-present	International Society for NeuroVirology	Member
2015-2016	Postdoctoral Association, VCU	Treasurer
2014-2016	Postdoctoral Association, VCU	Travel Awards Chair
2014-2017	National Postdoctoral Association	Member
2013-present	Society on NeuroImmune Pharmacology	Member
2013-present	College on Problems of Drug Dependence	Member
2011-present	International Narcotics Research Conference	Member
2008-2009	American Association for the Advancement of Science	Member
2008-2011	Psi Chi National Psychology Honors Society	Member
2007-2011	NorthEast Under/grad Research Organization for Neuroscience: Program Officer	
2006-2008	Society for Behavioral Neuroendocrinology	Member
2006-present	Society for Neuroscience	Member
2004-2011	NorthEast Under/graduate Research Organization for Neuroscience: Member	

INVITED TALKS (*also served as symposium chair)

2023	Drexel University	Philadelphia, PA
2022	MS Nano-Bio & ImmunoEngineering Res. Consortium	Oxford, MS
2021	University of Mississippi Medical Center	Telecast to Jackson, MS
2021	University of Arkansas for Medical Sciences	Telecast to Little Rock, AR
2021	Central Michigan University - Grand Rounds	Telecast to Mount Pleasant, MI
2020	City University of New York/Hunter College	Telecast to New York, NY
2020	University of Southern Mississippi	Hattiesburg, MS
2019	International Society for NeuroVirology	Atlanta, GA
2019	Society for Neuroscience	Chicago, IL
2019	American Society for Microbiology-South Central Branch	Oxford, MS
2018	University of California, San Diego	Telecast to San Diego, CA
2018	Mississippi IDeA Conference	Jackson, MS
2018	University of Mississippi, Neuroscience Showcase	University, MS
2018	UM/UMMC Research Day	Jackson, MS
2018*	American Society for Neurochemistry	Riverside, CA
2018	University of Mississippi, Infectious Disease Brown-Bag	University, MS
2018	Winter Conference on Brain Research	B.C., Canada
2017	Society for Neuroscience	Washington, D.C.
2017	University of Mississippi, Neuroscience Brown-Bag	University, MS
2017	University of Nebraska Medical Center	Omaha, NE
2017	University of Alabama at Birmingham	Birmingham, AL
2017	University of Mississippi	University, MS
2016	Society for Neuroscience	San Diego, CA
2015	Brain, Immunology, and Glia Meeting	Richmond, VA
2014	Virginia Commonwealth University	Richmond, VA
2012	Bio-Science & Analytics of South Florida group	Palm Beach, FL
2012*	The College on Problems of Drug Dependence	Palm Springs, CA
2009	Torrey Pines Institute for Molecular Studies	Port Saint Lucie, FL

2009	Annual Meeting of N.E.U.R.O.N.	New York, NY
2009	International Meeting of Steroids and Nervous System	Turin, Italy
2008	Stonehill College	Easton, MA
2007	University of Nevada Las Vegas	Las Vegas, NV
2007	International Meeting of Steroids and Nervous System	Turin, Italy
2006	Annual Meeting of N.E.U.R.O.N.	New York, NY

PATENTS

Int'l Patent: ALLOPREGNANOLONE ANALOGUES FOR HIV VIREMIA AND NEUROTOXICITY PROTECTION

Int'l Publication No.: WO 2023/023650 A1

Int'l Publication Date: February 23, 2023

Inventor(s): Hoang Le, Jason Paris, Fakhri Mahdi, Md. Imdadul Khan

U.S. Provisional Patent: RED BLOOD CELL-HITCHHIKING IONIC LIQUID COATED NANOPARTICLES FOR CROSSING THE BLOOD BRAIN BARRIER

Serial No.: 63/373,609; Filing Date: August 26, 2022

Inventor(s): Eden Elizabeth Louise Tanner; Christine Hamadani; Jason Paris

U.S. Provisional Patent: ORALLY BIOAVAILABLE, BRAIN-PENETRANT COMPOUND WITH SELECTIVITY FOR THE CANNABINOID TYPE 2 RECEPTOR WITH POTENTIAL USE TOWARDS VISCERAL PAIN MANAGEMENT AND NEURODEGENERATIVE DISORDERS

Serial No.: 63/324,392; Filing Date: March 28, 2022

Inventor(s): Mohamed Ali Mohamed Ibrahim; Jason Paris; Larry Walker

PEER-REVIEWED PUBLICATIONS (*h*-index = 33; *Shared first-authorship)

Current Most Relevant Contributions:

84. Qrareya AN*, Moss E*, Mahdi F, Salahuddin MF, Hu D, De Leon MA, Wanas AS, Radwan MM, ElSohly MA, Ashpole NM, **Paris JJ**. (2025). Sex differences in the capacity of minor phytocannabinoids to attenuate nociceptive insults in HIV-1 Tat-expressing mice. *NeuroImmun Pharmacol Ther. In press*. doi: 10.1515/nipt-2024-0025.
83. Salahuddin MF, Bugingo R, Mahdi F, Spencer D, Manzar MD, **Paris JJ**. (2025). Physiological and Psychological Impacts of Shift Work Among Student Pharmacists: Sex Differences in Stress and Health Outcomes. *Psychiatry Int.* 6(2):47. doi: 10.3390/psychiatryint6020047.
82. Mahdi F, Shariat-Madar Z, **Paris JJ**. (2025). HIV-1 Tat Impairment of Mitochondrial Respiration via Complexes I and II Can Be Ameliorated by Allopregnanolone in Opioid-Exposed or Opioid-Naïve Cells and Mice. *Antioxidants (Basel)*. 31;14(4):420. doi: 10.3390/antiox14040420.
81. Hahn YK, Nass SR, Marks WD, **Paris JJ**, Hauser KF, Knapp PE. (2024). Sex related differences in cognitive deficits: Disrupted Arc/Arg3.1 signaling in an HIV model. *Neurosci Lett*. 2025 845:138071. doi: 10.1016/j.neulet.2024.138071.
80. Boullard NG, **Paris JJ**, Shariat-Madar Z, Mahdi F. (2024). Increased Prolylcarboxypeptidase Expression Can Serve as a Biomarker of Senescence in Culture. *Molecules*. 2024 29(10):2219. doi: 10.3390/molecules29102219.
79. Hamadani CM, Mahdi F, Merrell A, Flanders J, Cao R, Vashisth P, Dasanayake GS, Darlington DS, Singh G, Pride MC, Monroe WG, Taylor GR, Hunter AN, Roman G, **Paris JJ**, Tanner EEL. (2024). Ionic Liquid Coating-Driven Nanoparticle Delivery to the Brain: Applications for NeuroHIV. *Adv Sci (Weinh)*. 11(23):e2305484. doi: 10.1002/adv.202305484.
78. Paudel P, Pandey P, **Paris JJ**, Ashpole NM, Mahdi F, Tian JM, Lee J, Wang M, Xu M,

- Chittiboyina AG, Khan IA, Ross SA, Li XC. (2023). Cannabinoid Receptor Type II Ligands from Sandalwood Oil and Synthetic α -Santalol Derivatives. *J Nat Prod.* 86(7):1786-1792. doi: 10.1021/acs.jnatprod.3c00282.
77. Akins NS, Salahuddin MF, Pandey P, Kim SJ, Mahdi F, Khan MIH, Moss EM, Worth CJ, Keane MM, Chittiboyina AG, Doerksen RJ, **Paris JJ**, Le HV. (2023). Alleviation of Cocaine Withdrawal and Pertinent Interactions between Salvinorin-Based Antagonists and Kappa Opioid Receptor. *ACS Chem Neurosci.* 14(5):958-976. doi: 10.1021/acchemneuro.2c00806.
 76. Moss EM, Mahdi F, Worth CJ, **Paris JJ**. (2023). Physiological Corticosterone Attenuates gp120-Mediated Microglial Activation and Is Associated with Reduced Anxiety-Like Behavior in gp120-Expressing Mice. *Viruses.* 15(2):424. doi: 10.3390/v15020424.
 75. Ahmed HA, Ticar BF, Black I, Mahdi F, Shami AA, Misra SK, Heiss C, **Paris JJ**, Sharp JS, Azadi P, Pomin VH. (2023). Structural characterization and biological activity of an α -glucan from the mollusk *Marcia hiantina* (Lamarck, 1818). *Glycoconj J.* 40(1):33-46. doi: 10.1007/s10719-022-10092-6.
 74. Khan MIH, Mahdi F, Penfornis P, Akins NS, Hossain MI, Kim SJ, Sulochana SP, Adam AT, Tran TD, Tan C, Paolo Claudio P, **Paris JJ**, Le HV. Synthesis and biological evaluation of tert-butyl ester and ethyl ester prodrugs of L- γ -methyleneglutamic acid amides for cancer. *Bioorg Med Chem.* 78:117137. doi: 10.1016/j.bmc.2022.117137
 73. Toma W*, **Paris JJ***, Warncke UO, Nass SR, Caillaud M, McKiver B, Ondo O, Bagdas D, Bigbee J, Knapp PE, Hauser KF, Damaj MI. (2022). Persistent sensory changes and sex differences in transgenic mice conditionally expressing HIV-1 Tat regulatory protein. *Exp Neurol.* 358:114226. doi: 10.1016/j.expneurol.2022.114226.
 72. Qrareya AN, Wise NS, Hodges ER, Mahdi F, Stewart JA, **Paris JJ**. (2022). HIV-1 Tat upregulates the receptor for advanced glycation end products and superoxide dismutase-2 in the heart of transgenic mice. *Accepted at Viruses.*
 71. Leibrand CR*, **Paris JJ***, Jones AM, Ohene-Nyakoc M, Rademeyera KM, Nass SR, Kim WK, Knapp PE, Hauser KF, McRae M (2022). Independent actions by HIV-1 Tat and morphine to increase recruitment of monocyte-derived macrophages into the brain in a region-specific manner. *Accepted at Neurosci. Lett.*
 70. Qrareya AN, Mahdi F, Kaufman MJ, Ashpole NM, **Paris JJ**. (2022). Age-related neuroendocrine, cognitive, and behavioral co-morbidities are promoted by HIV-1 Tat expression in male mice. *Aging (Albany NY).* 14(13):5345-5365. doi: 10.18632/aging.204166.
 69. Ospanov M, Sulochana SP, **Paris JJ**, Rimoldi JM, Ashpole NM, Walker L, Ross SA, Shilabin AG, Ibrahim MA. (2022). Identification of an orally bioavailable, brain-penetrant compound with selectivity for the cannabinoid type 2 receptor. *Molecules.* 27(2):509. doi: 10.3390/molecules27020509
 68. Akins NS, Mishra N, Harris HM, Dudhipala N, Kim SJ, Keasling AW, Majumdar S, Zjawiony JK, **Paris JJ**, Ashpole NM, Le HV. (2022). 6,5-Fused Ring, C2-Salvinorin Ester, Dual Kappa and Mu Opioid Receptor Agonists as Analgesics Devoid of Anxiogenic Effects. *ChemMedChem.* 17(7):e202100684. doi: 10.1002/cmdc.202100684
 67. Salahuddin MF, Qrareya AN, Mahdi F, Moss E, Akins NS, Li J, Le HV, **Paris JJ**. (2021). Allopregnanolone and NeuroHIV: Potential Benefits of Neuroendocrine Modulation in the Era of Antiretroviral Therapy. *J Neuroendocrinol.* doi: 10.1111/jne.13047
 66. Pomin VH, Mahdi F, Jin W, Zhang F, Linhardt RJ, **Paris JJ**. (2021). Red algal sulfated galactan binds and protects neural cells from HIV-1 gp120 and Tat. *Pharmaceuticals (Basel).* 14(8):714. doi: 10.3390/ph14080714
 65. Salahuddin MF, Mahdi F, Sulochana SP, **Paris JJ**. (2021). HIV-1 Tat protein promotes neuroendocrine dysfunction concurrent with the potentiation of oxycodone's psychomotor effects in female mice. *Viruses.* 13(5):813. doi: 10.3390/v13050813
 64. **Paris JJ**, Chen X, Anderson J, Qrareya AN, Mahdi F, Du F, McLaughlin JP, Kaufman MJ. (2021). *In vivo* proton magnetic resonance spectroscopy detection of metabolite abnormalities

- in aged Tat-transgenic mouse brain. *GeroScience*. 43(4):1851-1862. doi: 10.1007/s11357-021-00354-w
63. Marks WD, **Paris JJ**, Barbour AJ, Moon J, McLane VD, Lark A, Nass SR, Zhang J, Yarotsky V, McQuiston AR, Knapp PE, Hauser KF. (2021). HIV-1 Tat and morphine differentially disrupt pyramidal cell structure and function and spatial learning in hippocampal area CA1: Effects of sustained morphine exposure versus withheld. *eNeuro*. 8(3):ENEURO.0547-20.2021. doi: 10.1523/ENEURO.0547-20.2021
 62. Hossain MI, Thomas AG, Mahdi F, Adam AT, Woodard MM, **Paris JJ**, Slusher BS, Le HV. (2021). An efficient synthetic route to L- γ -methyleneglutamine and its amide derivatives, and their anticancer activity. *RSC Adv*. 11, 7115-7128. doi: 10.1039/D0RA08249J
 61. Salahuddin MF, Mahdi F, **Paris JJ**. (2020). HIV-1 Tat dysregulates the hypothalamic-pituitary-adrenal stress axis and potentiates oxycodone-mediated psychomotor and anxiety-like behavior of male mice. *Int J Mol Sci*. 21(21):8212. doi: 10.3390/ijms21218212
 60. Qrareya AN, Mahdi F, Kaufman M, Ashpole NM, **Paris JJ**. (2020). HIV-1 Tat promotes age-related cognitive, anxiety-like, and antinociceptive impairments in female mice that are moderated by aging and endocrine status. *GeroScience*. 43(1):309-32. doi: 10.1007/s11357-020-00268-z
 59. Bagdas D*, **Paris JJ***, Carper M, Wodarski R, Rice AS, Knapp PE, Hauser KF. (2020). Conditional expression of HIV-1 Tat in the mouse alters the onset and progression of tonic, inflammatory, and neuropathic pain in sex-dependent manner. *Eur J Pain*. doi: 10.1002/ejp.1618
 58. Cissom C, **Paris JJ**, Shariat-Madar Z. (2020). The role of dynorphins in the cardiovascular system: An update on current knowledge. *Curr Mol Med*. 20:1-16. doi: 10.2174/1566524019666191028122559
 57. **Paris JJ**, Liere P, Kim S, Mahdi F, Buchanan M, Nass SR, Qrareya AN, Salahuddin MF, Pianos A, Fernandez N, Shariat-Madar Z, Knapp PE, Schumacher M, Hauser KF. (2020). Pregnane steroidogenesis is altered by HIV-1 Tat and morphine: Physiological allopregnanolone is protective against neurotoxic and psychomotor effects. *Neurobiol Stress*. 12:100211. doi: 10.1016/j.ynstr.2020.100211
 56. Salahuddin MF, Qrareya AN, Mahdi F, Jackson D, Foster M, Vujanovic T, Box JG, **Paris JJ**. (2020). Combined HIV-1 Tat and oxycodone activate the hypothalamic-pituitary-adrenal and -gonadal axes and promote psychomotor, affective, and cognitive dysfunction in female mice. *Horm Behav*. 119:104649. doi: 10.1016/j.yhbeh.2019.104649
 55. Leibrand CR, **Paris JJ**, Jones AM, Masuda QN, Halquist MS, Kim WK, Knapp PE, Kashuba ADM, Hauser KF, McRae M. (2019). HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity. *J Neurovirol*. 25(4):560-577. doi: 10.1007/s13365-019-00757-8.
 54. Patel SH, Ismaiel OA, Mylott Jr WR, Yuan M, McClay JL, **Paris JJ**, Hauser KF, McRae M. (2019). Cell-type specific differences in antiretroviral penetration and the effects of HIV-1 Tat and morphine among primary human brain endothelial cells, astrocytes, pericytes, and microglia. *Neurosci Lett*. 712:134475. doi: 10.1016/j.neulet.2019.134475
 53. Zou S, Balinang JM, **Paris JJ**, Hauser KF, Fuss B, Knapp PE. (2019). Effects of HIV-1 Tat on oligodendrocyte viability are mediated by CaMKII β -GSK3 β interaction. *J Neurochem*. 149(1):98-110. doi: 10.1111/jnc.14668.
 52. Gonek M, McLane VD, Stevens DL, Lippold K, Akbarali HI, Knapp PE, Dewey WL, Hauser KF, **Paris JJ**. (2018). CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and reward. *Brain Behav Immun*. 69:124-138. doi: 10.1016/j.bbi.2017.11.006
 51. McRae M, LaFratta LM, Nguyen BM, **Paris JJ**, Hauser KF, Conway DE. (2018). Characterization of cell-cell junction changes associated with the formation of a strong endothelial barrier. *Tissue Barriers*. e1405774. doi: 10.1080/21688370.2017.1405774

50. Wodarski R, Bagdas D, **Paris JJ**, Pheby T, Toma W, Xu R, Damaj MI, Knapp PE, Rice ASC, Hauser KF. (2018). Reduced intra-epidermal nerve fibre density, glial activation, and sensory changes in human immunodeficiency virus (HIV) type-1 Tat-expressing female mice: Involvement of Tat during early stages of HIV-associated painful sensory neuropathy. *Pain Rep.* 14;3(3):e654. doi: 10.1097/PR9.0000000000000654.
49. Leibrand CR*, **Paris JJ***, Ghandour MS, Knapp PE, Kim WK, Hauser KF, McRae M. (2017). HIV-1 Tat disrupts blood-brain barrier integrity and increases phagocytic perivascular macrophages and microglia in the dorsal striatum of transgenic mice. *Neurosci Lett.* 640:136-143. doi: 10.1016/j.neulet.2016.12.073
48. McLaughlin JP, **Paris JJ**, Mintzopoulos D, Hymel KA, Kim JK, Cirino TJ, Gillis TE, Eans SO, Vitaliano GD, Medina JM, Krapf RC, Stacy HM, Kaufman MJ. (2017). Conditional HIV-Tat protein expression induces depression-like effects and oxidative stress. *Biol Psychiatry Cogn Neurosci Neuroimaging.* 2(7):599-609. doi: 10.1016/j.bpsc.2017.04.002
47. Schier CJ*, Marks WD*, **Paris JJ**, Barbour AJ, McLane VD, Maragos WF, McQuiston AR, Knapp PE, Hauser KF. (2017). Selective vulnerability of striatal D₂ versus D₁ dopamine receptor-expressing medium spiny neurons in HIV-1 Tat transgenic male mice. *J Neurosci.* 37(23):5758-5769. doi: 10.1523/JNEUROSCI.0622-17.2017
46. Hahn YK, **Paris JJ**, Lichtman AH, Hauser KF, Sim-Selley LJ, Selley DE, Knapp PE. (2016). Central HIV-1 Tat exposure elevates anxiety and fear conditioned responses of male mice concurrent with altered mu-opioid receptor mediated G-protein activation and β -arrestin 2 activity in the limbic forebrain and striatum. *Neurobiol Dis.* 92(PtB):124-36. doi: 10.1016/j.nbd.2016.01.014
45. Marks WD, **Paris JJ**, Schier CJ, Denton MD, Fitting S, McQuiston AR, Knapp PE, Hauser KF. (2016). HIV-1 Tat causes cognitive deficits and selective loss of parvalbumin, somatostatin, and neuronal nitric oxide synthase expressing hippocampal CA1 interneuron subpopulations. *J Neurovirol.* 2016;22(6):747-762. doi: 10.1007/s13365-016-0447-2
44. **Paris JJ**, Zou S, Hahn YK, Knapp PE, Hauser KF. (2016). 5 α -reduced progestogens ameliorate mood-related behavioral pathology, neurotoxicity, and microgliosis associated with exposure to HIV-1 Tat. *Brain Behav Immun.* 55:202-14. doi: 10.1016/j.bbi.2013.01.007
43. Carey AN, Liu X, Mintzopoulos D, **Paris JJ**, McLaughlin JP, Kaufman MJ. (2015). Conditional Tat protein brain expression in the GT-tg bigenic mouse induces cerebral fractional anisotropy abnormalities. *Curr HIV Res.* 13(1):3-9. doi: 10.2174/1570162X13666150126125244
42. Mediouni S, Jablonski J, **Paris JJ**, Clementz MA, Thenin-Houssier S, McLaughlin JP, Valente ST. (2015). Didehydro-Cortistatin A inhibits HIV-1 Tat mediated neuroinflammation and prevents potentiation of cocaine reward in Tat transgenic mice. *Curr HIV Res.* 13(1):64-79. doi: 10.2174/1570162X13666150121111548
41. **Paris JJ**, Singh HD, Carey AN, McLaughlin JP. (2015). Exposure to HIV-1 Tat in brain impairs sensorimotor gating and activates microglia in limbic and extralimbic brain regions of male mice. *Behav Brain Res.* 291:209-18. doi: 10.1016/j.bbr.2015.05.021
40. Fitting S, Zou S, El-Hage N, Suzuki M, **Paris JJ**, Schier CJ, Rodríguez JW, Rodríguez M, Knapp PE, Hauser KF. (2014). Opiate addiction therapies and HIV-1 Tat: interactive effects on glial [Ca²⁺]_i, oxyradical and neuroinflammatory chemokine production and correlative neurotoxicity. *Curr HIV Res.* 12(6):424-34. doi: 10.2174/1570162X1206150311161147
39. McLaughlin JP, Ganno ML, Eans SO, Mizrahi E, **Paris JJ**. (2014). HIV-1 Tat protein exposure potentiates ethanol-conditioned place preference and produces reinstatement in mice. *Curr HIV Res.* 12(6):415-23. doi: 10.2174/1570162X1206150311160133
38. **Paris JJ**, Carey AN, Shay CF, Gomes SM, He JJ, McLaughlin JP. (2014). Effects of conditional central expression of HIV-1 Tat protein to potentiate cocaine mediated psychostimulation and reward among male mice. *Neuropsychopharmacology.* 39(2):380-8. doi: 10.1038/npp.2013.201
37. **Paris JJ**, Fenwick J, McLaughlin JP. (2014). Estrous cycle and HIV-1 Tat protein influence

- cocaine-conditioned place preference and induced locomotion of female mice. *Curr HIV Res.* 12(6):388-96. doi: 10.2174/1570162X13666150121105221
36. **Paris JJ**, Fenwick J, McLaughlin JP. (2014). Progesterone protects normative anxiety-like responding among female mice that conditionally express the HIV-1 regulatory protein, Tat, in the CNS. *Horm Behav.* 65(5):445-53. doi: 10.1016/j.yhbeh.2014.04.001
 35. **Paris JJ**, Singh HD, Ganno ML, Jackson P, McLaughlin JP. (2014). Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 accessory protein, Tat. *Psychopharmacology.* 231(11):2349-60. doi: 10.1007/s00213-013-3385-1
 34. Carey AN, Liu X, Mintzopoulos D, **Paris JJ**, Muschamp JW, McLaughlin JP, Kaufman MJ. (2013). Conditional Tat protein expression in the GT-tg bigenic mouse brain induces gray matter density reductions. *Prog Neuropsychopharmacol Biol Psychiatry.* 43:49-54. doi: 10.1016/j.pnpbp.2012.12.018

Additional Peer-Reviewed Contributions:

33. Frye CA, Qrareya AN, Llaneza DC, **Paris JJ**. (2020). Central actions of 3 α ,5 α -THP involving NMDA and GABA_A receptors regulate affective and sexual behavior of female rats. *Front Behav Neurosci.* 14:11. doi: 10.3389/fnbeh.2020.00011.
32. Lynn CD, **Paris JJ**, Frye CA, Schell LM. (2015). Religious-commitment signaling and impression management amongst Pentecostals: Relationships to salivary cortisol and alpha-amylase. *J Cogn Cult.* 15(3-4):299-319. doi: 10.1163/15685373-12342152
31. **Paris JJ**, Eans SO, Mizrahi E, Reilley KJ, Ganno ML, McLaughlin JP. (2013). Central administration of angiotensin IV rapidly enhances novel object recognition among mice. *Neuropharmacology.* 70C:247-253. doi: 10.1016/j.neuropharm.2013.01.025
30. Stuart JM, **Paris JJ**, Frye CA, Bradshaw H. (2013). Brain levels of prostaglandins, endocannabinoids, and related lipids are affected by mating strategies. *Int J Endocrinol.* 2013:436252. doi: 10.1155/2013/436252
29. Frye CA, **Paris JJ**. (2011). Progesterone turnover to its 5 α -reduced metabolites in the ventral tegmental area of the midbrain is essential for initiating social and affective behavior and progesterone metabolism in female rats. *J Endocrinol Invest.* 24(7):e188-99. doi: 10.3275/7334
28. Frye CA, **Paris JJ**. (2011). Effects of neurosteroid actions at N-methyl-D-aspartate and GABA_A receptors in the midbrain ventral tegmental area for anxiety-like and mating behavior of female rats. *Psychopharmacology (Berl).* 213(1):93-103. doi: 10.1007/s00213-010-2016-3
27. Frye, CA, **Paris, JJ**, Osborne, DM, Campbell, JC, Kippin, TE. (2011). Prenatal stress alters progesterone to mediate susceptibility to sex-typical, stress-sensitive disorders, such as drug abuse: a review. *Front Psychiatry.* 2:52. doi: 10.3389/fpsy.2011.00052
26. Frye CA, **Paris JJ**, Walf AA, Rusconi JC. (2011). Effects and mechanisms of 3 α ,5 α -THP on emotion, motivation, and reward functions involving pregnane xenobiotic receptor. *Front Neurosci.* 5:136. doi: 10.3389/fnins.2011.00136
25. Lynn CD, **Paris JJ**, Frye CA, Schell LM. (2011). Glossolalia is associated with differences in biomarkers of stress and arousal among apostolic pentecostals. *Religion Brain Behav.* 1(3):173-91. doi: 10.1080/2153599X.2011.639659
24. McFadden LM, **Paris JJ**, Mitzelfelt MS, McDonough S, Frye CA, Matuszewich L. (2011). Sex-dependent effects of chronic unpredictable stress in the water maze. *Physiol Behav.* 102(3-4):266-75. doi: 10.1016/j.physbeh.2010.10.022
23. **Paris JJ**, Brunton PJ, Russell JA, Frye CA. (2011). Immune stress in late pregnant rats decreases length of gestation, fecundity, and alters later cognitive and affective behaviour of surviving offspring. *Stress.* 14(6):652-64. doi: 10.3109/10253890.2011.628719
22. **Paris JJ**, Brunton PJ, Russell JA, Walf AA, Frye CA. (2011). Inhibition of 5 α -reductase activity in late pregnancy decreases gestational length and fecundity and impairs object memory and central progesterone milieu of juvenile rat offspring. *J Neuroendocrinol.* 23(11):1079-90. doi:

10.1111/j.1365-2826.2011.02219.x

21. **Paris JJ**, Frye CA. (2011). Gestational exposure to variable stressors produces decrements in cognitive and neural development of juvenile male and female rats. *Curr Top Med Chem.* 11(13):1706-13. doi: 10.2174/156802611796117649
20. **Paris JJ**, Frye CA. (2011). Juvenile offspring of rats exposed to restraint stress in late gestation have impaired cognitive performance and dysregulated progesterone formation. *Stress.* 14(1):23-32. doi: 10.3109/10253890.2010.512375
19. **Paris JJ**, Reilley KJ, McLaughlin JP. (2011). Kappa opioid receptor-mediated disruption in novel object recognition: Relevance for psychostimulant treatment. *J Addict Res Ther.* S4. doi: 10.4172/2155-6105.S4-007
18. **Paris JJ**, Walf AA, Frye CA. (2011). II. Cognitive performance of middle-aged female rats is influenced by capacity to metabolize progesterone in the prefrontal cortex and hippocampus. *Brain Res.* 1379:149-63. doi: 10.1016/j.brainres.2010.10.099
17. Walf AA, **Paris JJ**, Llaneza DC, Frye CA. (2011). I. Levels of 5 α -reduced progesterone metabolite in the midbrain account for variability in reproductive behavior of middle-aged female rats. *Brain Res.* 1379:137-48. doi: 10.1016/j.brainres.2010.11.004
16. Walf AA, **Paris JJ**, Rhodes ME, Simpkins JW, Frye CA. (2011). Divergent mechanisms for trophic actions of estrogens in the brain and peripheral tissues. *Brain Res.* 1379:119-36. doi: 10.1016/j.brainres.2010.11.081
15. Franco C, **Paris JJ**, Wulfert E, Frye CA. (2010). Male gamblers have significantly greater salivary cortisol before and after betting on a horse race, than do female gamblers. *Physiol Behav.* 99(2):225-9. doi: 10.1016/j.physbeh.2009.08.002
14. Frye CA, Walf AA, **Paris JJ**. (2010). Conjugated equine estrogen, with medroxyprogesterone acetate, enhances formation of 5 α -reduced progestogens and reduces anxiety-like behavior of middle-aged rats. *Behav Pharmacol.* 21(5-6):530-9. doi: 10.1097/FBP.0b013e32833e0a23
13. Kohtz AS, **Paris JJ**, Frye CA. (2010). Low doses of cocaine decrease, and high doses increase, anxiety-like behavior and brain progesterone levels among intact rats. *Horm Behav.* 57(4-5):474-80. doi: 10.1016/j.yhbeh.2010.02.005
12. Lynn CD, **Paris JJ**, Frye CA, Schell LM. (2010). Salivary α -amylase and cortisol among pentecostals on a worship and nonworship day. *Am J Hum Biol.* 22(6):819-22. doi: 10.1002/ajhb.21088
11. **Paris JJ**, Franco C, Sodano R, Freidenberg B, Gordis E, Anderson DA, Forsyth JP, Wulfert E, Frye CA. (2010). Sex differences in salivary cortisol in response to acute stressors among healthy participants, in recreational or pathological gamblers, and in those with posttraumatic stress disorder. *Horm Behav.* 57(1):35-45. doi: 10.1016/j.yhbeh.2009.06.003
10. **Paris JJ**, Franco C, Sodano R, Frye CA, Wulfert E. (2010). Gambling pathology is associated with dampened cortisol response among men and women. *Physiol Behav.* 99(2):230-3. doi: 10.1016/j.physbeh.2009.04.002
9. Frye CA, **Paris JJ**. (2009). Infusions of bicuculline to the ventral tegmental area attenuates sexual, exploratory, and anti-anxiety behavior of proestrous rats. *Pharmacol Biochem Behav.* 93(4):474-81. doi: 10.1016/j.pbb.2009.06.012
8. Frye CA, **Paris JJ**, Rhodes ME. (2009). Increasing 3 α ,5 α -THP following inhibition of neurosteroid biosynthesis in the ventral tegmental area reinstates anti-anxiety, social, and sexual behavior of naturally receptive rats. *Reproduction.* 137(1):119-28. doi: 10.1530/REP-08-0250
7. **Paris JJ**, Frye CA. (2009). Alcohol dose-dependently enhances 3 α -androstenediol formation in frontal cortex of male rats concomitant with aggression. *Open Neuropsychopharmacol J.* 2:1-10. doi: 10.2174/1876523800902010001
6. Walf AA, **Paris JJ**, Frye CA. (2009). Nociceptive and anxiety-like behavior in reproductively competent and reproductively senescent middle-aged rats. *Gend Med.* 6(2):235-46. doi:

10.1016/j.genm.2009.03.002

5. Walf AA, **Paris JJ**, Frye CA. (2009). Chronic estradiol replacement to aged female rats reduces anxiety-like and depression-like behavior and enhances cognitive performance. *Psychoneuroendocrinology*. 34(6):909-16. doi: 10.1016/j.psyneuen.2009.01.004
4. Frye CA, **Paris JJ**, Rhodes ME. (2008). Estrogen is necessary for 5 α -pregnan-3 α -ol-20-one (3 α ,5 α -THP) infusion to the ventral tegmental area to facilitate social and sexual, but neither exploratory nor affective behavior of ovariectomized rats. *Pharmacol Biochem Behav*. 91(2):261-70. doi: 10.1016/j.pbb.2008.08.018
3. Frye CA, **Paris JJ**, Rhodes ME. (2008). Exploratory, anti-anxiety, social, and sexual behaviors of rats in behavioral estrus is attenuated with inhibition of 3 α ,5 α -THP formation in the midbrain ventral tegmental area. *Behav Brain Res*. 193(2):269-76. doi: 10.1016/j.bbr.2008.06.005
2. **Paris JJ**, Frye CA. (2008). Estrous cycle, pregnancy, and parity enhance performance of rats in object recognition or object placement tasks. *Reproduction*. 136(1):105-15. doi: 10.1530/REP-07-0512
1. Frye CA, **Paris JJ**, Rhodes ME. (2007). Engaging in paced mating, but neither exploratory, anti-anxiety, nor social behavior, increases 5 α -reduced progesterone concentrations in midbrain, hippocampus, striatum, and cortex. *Reproduction*. 133(3):663-74. doi: 10.1530/rep.1.01208

PUBLISHED ABSTRACTS

33. Hossein M, Mahdi F, Khan MI, Akins NS, Penfornis P, Kim SJ, Slusher BS, **Paris JJ**, Le HV, Claudio PP. (2021). Alleviation of Cocaine Withdrawal and Pertinent Interactions between Salvinorin-based Antagonists and Kappa Opioid Receptor. University of Mississippi eGrove Annual Poster Session.
https://egrove.olemiss.edu/cgi/viewcontent.cgi?article=1014&context=pharm_annual_posters_2021
32. Khan, Md Imdadul H.; Salahuddin, Mohammed F.; Akins, Nicholas S.; Mahdi, Fakhri; Kim, Seong Jong; Li, Jing; Paris, Jason J.; and Le, Hoang V., "Discovery of 5 α -pregnan-2 β ,3 α -diol-20-one as a neuroHIV Protective Agent" (2021). University of Mississippi Annual Poster Session 2021. 10. https://egrove.olemiss.edu/pharm_annual_posters_2021/10
31. Mohammed, Salahuddin; Mahdi, Fakhri; and Paris, Jason J., "HIV-1 Tat Protein Promotes Neuroendocrine Dysfunction Concurrent with the Potentiation of Oxycodone's Psychomotor Behavioral Effects in Female Transgenic Mice" (2021). University of Mississippi Annual Poster Session 2021. 6. https://egrove.olemiss.edu/pharm_annual_posters_2021/6
30. Qraeya, Alaa; Mahdi, Fakhri; Kaufman, Marc; Ashpole, Nicole M.; and Paris, Jason J., "Age-related Neuroendocrine, Cognitive, and Behavioral Co-Morbidities Are Promoted by HIV-1 Tat Expression in Male Mice" (2021). Annual Poster Session 2021. 5. https://egrove.olemiss.edu/pharm_annual_posters_2021/5
29. Mohammed, Salahuddin; Mahdi, Fakhri; and Paris, Jason, "Sex differences in the hypothalamic-pituitary-adrenal axis' response to stress in adult HIV Tat transgenic mice" (2021). Neuroscience Research Showcase. 16. https://egrove.olemiss.edu/neuro_showcase/16
28. Qraeya, Alaa N.; Mahdi, Fakhri; Ashpole, Nicole; and Paris, Jason, "Premature Age-Related Co-Morbidities In HIV-1 Tat Transgenic Mice That Are Moderated By Aging and Endocrine Status" (2021). Neuroscience Research Showcase. 14. https://egrove.olemiss.edu/neuro_showcase/14
27. Salahuddin, Mohammed; Mahdi, Fakhri; and Paris, Jason J., "R01. HIV-1 Tat Dysregulates the Hypothalamic-Pituitary-Adrenal Stress Axis and Potentiates Oxycodone-mediated Psychomotor and Anxiety-like Behavior of Male Mice" (2020). Annual Poster Session 2020. 1. https://egrove.olemiss.edu/pharm_annual_posters/1
26. Qraeya AN, Mahdi F, Kaufman M, Ashpole NM, **Paris JJ**. (2020). HIV-1 Tat expression, in

- aged mice, increases mechanical allodynia. Neither Tat nor aging impair thermal hyperalgesia. University of Mississippi.
<https://scholar.google.com/scholar?oi=bibs&cluster=14398043570884167795&btnI=1&hl=en>
25. Moss E, Mahdi F, **Paris JJ**. (2020). HIV-1 glycoprotein 120 promotes affective dysfunction in mice and medium spiny neuron necrosis. University of Mississippi Annual Poster Session. 4. https://egrove.olemiss.edu/pharm_annual_posters/4
 24. Sneed L, Mahdi F, Salahuddin M, **Paris JJ**, Shariat-Madar Z. (2020). HIV Tat protein activates plasma kallikrein-kinin system in the doxycycline-inducible astrocyte specific HIV-1 Tat transgenic mice. University of Mississippi Annual Poster Session. 3. https://egrove.olemiss.edu/pharm_annual_posters/3
 23. Qrarefa AN, Mahdi F, Ashpole NM, **Paris JJ**. (2020) HIV-1 Tat promotes age-related anxiety-like, antinociceptive, and neuromuscular impairments in aged male mice. University of Mississippi Annual Poster Session. 2. https://egrove.olemiss.edu/pharm_annual_posters/2
 22. Salahuddin M, Mahdi F, Qrarefa AN, **Paris JJ**. (2020). HIV-1 Tat dysregulates the hypothalamic-pituitary-adrenal stress axis and potentiates oxycodone-mediated psychomotor and anxiety-like behavior of male mice. University of Mississippi Neuroscience Research Showcase. 7. https://egrove.olemiss.edu/neuro_showcase/7
 21. McRae M, Jones AM, **Paris JJ**, Kim WK, Knapp PE, Kashuba AMD, Hauser KF, Leibrand CR (2019). Opiates and HIV-1 perturb the cellular/regional biodistribution of antiretrovirals in the brain by disrupting the blood-brain barrier and efflux transporter function. *J Neuroimmun Pharmacol.* 14(2):334.
 20. **Paris JJ**, Qrarefa AN, Mahdi F, Salahuddin MF. (2019). HIV-1 Tat promotes age-related cognitive, anxiety-like, and antinociceptive impairments in mice that are moderated by aging endocrine status. *J Neurovirol.* 25(1):S34-S35.
 19. Qrarefa AN, Lierre P, Kim S, Mahdi F, Buchanan ME, Knapp PE, Schumacher M, Hauser KF, **Paris JJ**. Allopregnanolone as a therapeutic target for neurological dysfunction caused by exposure to HIV-1-Tat and morphine in a mouse model. University of Mississippi Research Day. 2. <https://egrove.olemiss.edu/researchday/2019/posters/2>
 18. Cirino T, **Paris JJ**, McLaughlin JP. (2018). HIV-1 Tat modulates cognitive performance in an assay-dependent manner. *J Neuroimmune Pharmacol.* 13:S17.
 17. Kim S, Hahn YK, **Paris JJ**, Hauser KF, Knapp PE. (2018). Role of glial CCR5 in HIV-1 Tat and opiate-mediated neurotoxicity and behavioral phenotype. *J Neuroimmune Pharmacol.* 13:S43.
 16. Leibrand CR, **Paris JJ**, Masuda Q, Halquist M, Knapp PE, Kashuba AMD, Hauser KF, McRae M. (2018). HIV-1 Tat and morphine limit antiretroviral CNS levels despite increasing blood-brain barrier leakiness. *J Neuroimmune Pharmacol.* 13:S46.
 15. McLaughlin JP, Cirino TJ, Eans SO, Medina JM, Hymel KA, **Paris JJ**, Kaufman MJ. (2017). Brain exposure to HIV-1 Tat protein potentiates the psychostimulant effects of morphine, modulates consumption and reinstates extinguished reward-seeking. *J Neuroimmun Pharmacol.* 12:S15.
 14. Leibrand CR, **Paris JJ**, Knapp PE, Kim WK, Hauser KF, McRae MP. (2016). HIV-1 Tat causes regional differences in phagocytosis by perivascular macrophages and microglia and causes disruption of the blood-brain barrier. *J Neurovirol* 22:S42-S43.
 13. Marks WD, Barbour AJ, **Paris JJ**, Schier CJ, Denton MD, Fitting S, McQuiston AR, Knapp PE, Hauser KF. (2016). Interaction between HIV-1 Tat and morphine causes disruption of GABAergic systems within CA1. *J Neurovirol* 22:S48-S48.
 12. McLaughlin JP, Ganno ML, **Paris JJ**, Zhang Y, Kreek MJ. (2016). Exposure to HIV-1 Tat protein potentiates the rewarding effects of morphine and reinstates extinguished conditioned place preference. *Drug Alcohol Depend.* 156:e147.
 11. **Paris JJ**, Balinang JM, Zou SP, Knapp PE, Hauser KF. (2016). Allopregnanolone attenuates

combined neurotoxicity associated with morphine and HIV-1 Tat in human cells. *J Neurovirol* 22:S59-S60.

10. Schier C, Marks W, **Paris JJ**, McQuiston AR, Knapp PE, Hauser KF. (2015). Selective vulnerability of D1-and D2-expressing medium spiny neurons after Tat ± morphine treatments. *J Neurovirol*. 21:S67-S68.
9. McLaughlin JP, Ganno ML, Eans SO, Medina JM, Stacy H, Gillis T, Rock A, Mintzopoulos D, **Paris JJ**, Kaufman MJ. (2015). CNS exposure to HIV-1 Tat protein modulates forebrain glutamate levels and increases depression-like behavior. *J Neuroimmune Pharmacol*. 10:S86.
8. McLaughlin JP, Ganno ML, Eans SO, **Paris JJ**, Singh HD. (2014). HIV-1 Tat protein expression in mouse brain potentiates ethanol reward and reinstates extinguished ethanol-seeking behavior. *Drug Alcohol Depend*. 140:e141-e142.
7. McLaughlin JP, **Paris JJ**, Carey AN. (2014). Conditional central expression of HIV-1 Tat protein potentiates cocaine-and ethanol-mediated reward and reinstates extinguished reward-seeking behavior. *J Neuroimmune Pharmacol*. 9(1):36-37.
6. **Paris JJ**, Carey AN, McLaughlin JP. (2014). Cocaine-seeking is dose dependently enhanced by HIV-1 Tat protein expression in male and female mice. *Drug Alcohol Depend*. 140:e168.
5. **Paris JJ**, Ganno ML, Fenwick J, Jackson P, McLaughlin JP. (2014). Central induction of the HIV-1 regulatory protein, Tat, promotes steroid-sensitive anxiety-like behavior among male and female mice. *J Neuroimmune Pharmacol*. 9(1):42-43.
4. Frye CA, Nash S, **Paris JJ**, Rhodes ME. (2008). Effects of anti-epileptic drugs on androgens levels and androgen-dependent sexual, cognitive and affective behavior, of male rats. *Neurology*. 70(11):A455-A456.
3. Frye CA, **Paris JJ**. (2006). 3 α -androstenediol may underlie some of testosterone's positive hedonic and/or drug-related effects. *Alcohol Clin Exp Res*. 30(9):54A.
2. **Paris JJ**, Frye CA. (2006). Co-administration of testosterone and alcohol to male rats enhances aggression and increases circulating levels of testosterone and its metabolites. *Alcohol Clin Exp Res*. 30(9):133A.
1. **Paris JJ**, Russell JA, Frye CA. (2006). Stress, inhibition of 5 α -reductase, and gestation outcome in rats. *Front Neuroendocrinol*. 27(1):38.

EDITORIALS

2. Kaufman MJ, Qrareya AN, **Paris JJ**. (2022). HIV-Tat protein-accelerated aging. *Aging* (Albany NY). 14(11):4618-4619. doi: 10.18632/aging.204105.
3. McLaughlin JP, **Paris JJ**. Contribution of HIV-Tat protein to HIV-sequelae (part 2). *Curr HIV Res*. 2015;13(1):2. doi: 10.2174/1570162x1301150317101233
1. McLaughlin JP, **Paris JJ**. Contribution of HIV-Tat protein to HIV-sequelae (part 1). *Curr HIV Res*. 2014;12(6):377. doi: 10.2174/1570162x1206150311152342

BOOK CHAPTERS

2. **Paris JJ**. (2024). HIV-associated neuroendocrine dysfunction. In: Hu G, Xiong H, Buch S (Eds.), *HIV-Associated Neurocognitive Disorders*. Elsevier, Amsterdam, Netherlands. ISBN: 9780323997447
1. Hymel KA, **Paris JJ**, McLaughlin JP. (2016). Modulation of opioid analgesic reward by inflammatory agents. In: Preedy VR (Ed.), *Neuropathology of Drug Addiction and Substance Misuse* (Vol. 3). Academic Press, New York. doi: 10.1016/B978-0-12-800634-4.00055-X

ADDITIONAL SERVICE TO PROFESSIONAL PUBLICATIONS

Guest Editor: Special Issue, *Addiction Neuroscience*, "Endocrine Mechanisms Driving Sex Differences in Addiction" Currently Finalizing Issue.

Guest Editor: Special Issue, *Current HIV Research*, "Contribution of HIV-Tat Protein to HIV-

Sequelae" Part 1 [2014, Volume 12(6)] and Part 2 [2015, Volume 13(1)].

Ad hoc journal reviewer: Brain Behavior and Immunity, Behavioural Brain Research, Biological Psychiatry, Cells, Current HIV Research, Current Opinion in Endocrine and Metabolic Research, Drug Delivery, Experimental Neurology, Hormones and Behavior, International Journal of Developmental Neuroscience, International Journal of Endocrinology, International Journal of HIV/AIDS & Clinical Research, iScience, JAIDS: Journal of Acquired Immune Deficiency Syndromes, Journal of Developmental Origins of Health and Disease, Journal of Intercultural Ethnopharmacology, Journal of Psychiatry and Neuroscience, Neurobiology of Disease, Neuropharmacology, NeuroToxicology, Neuroscience Letters, Nutrients, Pharmacology Biochemistry and Behavior, Physiology and Behavior, Regulatory Toxicology and Pharmacology, Science Advances, Toxicological Sciences, Virologica Sinica

MEDIA RELEASES

- "Mississippi researchers on the verge of groundbreaking HIV treatment" (2023) Magnolia State Live. Published online 9/23/23. <https://magnoliastatelive.com/2023/09/23/mississippi-researchers-on-the-verge-of-groundbreaking-hiv-treatment/>
- "Grant allows researchers to study cannabis pain relief" (2022) The Oxford Eagle. Whitney Tarp (author). Published in print 1/12/22.
- "This Federally-funded Study Will Test Whether Cannabis Can Treat HIV-related Pain" (2022) Analytical Cannabis. Leo Bear-McGuinness (author). Published online 1/6/22. <https://www.analyticalcannabis.com/news/this-federally-funded-study-will-test-whether-cannabis-can-treat-hiv-related-pain-313578>
- "University of Mississippi receives \$1.37M grant to study cannabis pain relief" (2022). CBS News 12, WJTV. Rachel Hernandez (author). Published online 1/5/22. <https://www.wjtv.com/news/state/university-of-mississippi-receives-1-37m-grant-to-study-cannabis-pain-relief/>
- "Professor works to reverse impact of opioids on HIV" (2019) The Oxford Eagle. Whitney Tarp (author). Published in print 1/8/19. <https://news.olemiss.edu/pharmacology-professor-works-reverse-impact-opioids-hiv/>
- "A HIV protein may increase craving for abused drugs" (2013) Press Release from Nature Publishing Group: http://www.nature.com/npp/press_releases/aug_13.pdf
- "HIV protein boosts cocaine's effect" (2013) The Scientist: <http://www.the-scientist.com/?articles.view/articleNo/37070/title/HIV-Protein-Boosts-Cocaine-s-Effect/>

REFERENCES (Available Upon Request)

Available Upon Request

